

CLAIMS

1. An antibody or antibody fragment that binds a KIR3DL2 polypeptide, comprising:
 - (a) a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 31; and
 - 5 (b) a light chain variable region comprising an amino acid sequence of SEQ ID NOs: 25 or 26.
2. An antibody according to Claim 1, in which the antibody is a full length antibody comprising a heavy chain variable region (VH) fused to a human gamma 1 constant region and a light chain variable region (VL) fused to a human kappa constant region.
- 10 3. An antibody according to any preceding claim, in which the antibody comprises a human heavy chain constant region comprising amino acid substitution(s) that increase binding to a human FcγIIIA (CD16) receptor, in which the substitution is selected from a substitution at any one or more of positions 221, 239, 243, 247, 255, 256, 258, 267, 268, 269, 270, 272, 276, 278, 280, 283, 285, 286, 289, 290, 292, 293, 294, 295, 296, 298, 300, 301, 303, 15 305, 307, 308, 309, 310, 311, 312, 316, 320, 322, 326, 329, 330, 332, 331, 332, 333, 334, 335, 337, 338, 339, 340, 359, 360, 370, 373, 376, 378, 392, 396, 399, 402, 404, 416, 419, 421, 430, 434, 435, 437, 438 and/or 439, in which numbering is according to Kabat.
4. A pharmaceutical composition comprising an antibody or antibody fragment according to any preceding claim, and a pharmaceutically acceptable carrier.
- 20 5. A pharmaceutical composition according to Claim 4 comprising: (a) about 0.05 mg/mL to about 10 mg/mL of an antibody according to any of Claims 1, 2 or 3; (b) buffer system; and (c) isotonic agent, at a pH of between 6.5 and 8.
6. An antibody according to Claim 1, 2 or 3 or a pharmaceutical composition according to Claim 4 or 5 for use in the treatment or prevention of disease in a patient in need thereof.
- 25 7. An antibody or pharmaceutical composition for use according to Claim 6, in which the disease is a peripheral T cell lymphoma.
8. An antibody or pharmaceutical composition for use according to Claim 6, in which the disease is selected from Mycosis fungoides and Sezary Syndrome.

9. A recombinant nucleic acid encoding an antibody or antibody fragment according to any of Claims 1, 2 or 3.
10. A host cell comprising a nucleic acid according to Claim 9.